Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

The diagnostic and prognostic role of flow cytometry in idiopathic and clonal cytopenia of undetermined significance (ICUS/CCUS): A single-center analysis of 79 patients.

Dimopoulos K, Hansen OK, Sjö LD, Saft L, Schjødt IM, Werner Hansen J, Grønbaek K.

Cytometry B Clin Cytom. 2019 Sep 3. doi: 10.1002/cyto.b.21842. [Epub ahead of print]

PMID:
31479199
2.

Revising flow cytometric mini-panel for diagnosing low-grade myelodysplastic syndromes: Introducing a parameter quantifying CD33 expression on CD34+ cells.

Ogata K, Sei K, Saft L, Kawahara N, Porta MGD, Chapuis N, Yamamoto Y.

Leuk Res. 2018 Aug;71:75-81. doi: 10.1016/j.leukres.2018.07.009. Epub 2018 Jul 10.

PMID:
30025279
3.

Challenges in Diagnosing Myelodysplastic Syndromes in the Era of Genetic Testing: Proceedings of the 13th Workshop of the European Bone Marrow Working Group.

Hebeda KM, Tzankov A, Boudova L, Saft L, Hasserjian RP, de Boer M, Fend F, Orazi A, Leguit R.

Pathobiology. 2019;86(1):62-75. doi: 10.1159/000489678. Epub 2018 Jul 6.

4.

Megakaryocytes harbour the del(5q) abnormality despite complete clinical and cytogenetic remission induced by lenalidomide treatment.

Scharenberg C, Jansson M, Saft L, Hellström-Lindberg E.

Br J Haematol. 2018 Feb;180(4):526-533. doi: 10.1111/bjh.15094. Epub 2018 Jan 29.

PMID:
29377069
5.

SF3B1-initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells.

Mortera-Blanco T, Dimitriou M, Woll PS, Karimi M, Elvarsdottir E, Conte S, Tobiasson M, Jansson M, Douagi I, Moarii M, Saft L, Papaemmanuil E, Jacobsen SEW, Hellström-Lindberg E.

Blood. 2017 Aug 17;130(7):881-890. doi: 10.1182/blood-2017-03-776070. Epub 2017 Jun 20.

6.

Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance.

de Swart L, Smith A, MacKenzie M, Symeonidis A, Neukirchen J, Mikulenková D, Vallespí T, Zini G, Paszkowska-Kowalewska M, Kruger A, Saft L, Fenaux P, Bowen D, Hellström-Lindberg E, Čermák J, Stauder R, Tatic A, Holm MS, Malcovati L, Mądry K, Droste J, Blijlevens N, de Witte T, Germing U.

Ann Hematol. 2017 Jul;96(7):1105-1112. doi: 10.1007/s00277-017-3009-7. Epub 2017 May 20.

7.

Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations.

Scharenberg C, Giai V, Pellagatti A, Saft L, Dimitriou M, Jansson M, Jädersten M, Grandien A, Douagi I, Neuberg DS, LeBlanc K, Boultwood J, Karimi M, Jacobsen SE, Woll PS, Hellström-Lindberg E.

Haematologica. 2017 Mar;102(3):498-508. doi: 10.3324/haematol.2016.152025. Epub 2016 Nov 24.

8.

CD274 (PD-L1)/PDCD1 (PD-1) expression in de novo and transformed diffuse large B-cell lymphoma.

Kwiecinska A, Tsesmetzis N, Ghaderi M, Kis L, Saft L, Rassidakis GZ.

Br J Haematol. 2018 Mar;180(5):744-748. doi: 10.1111/bjh.14432. Epub 2016 Nov 23. No abstract available.

PMID:
27879989
9.

Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group.

Westers TM, Cremers EM, Oelschlaegel U, Johansson U, Bettelheim P, Matarraz S, Orfao A, Moshaver B, Brodersen LE, Loken MR, Wells DA, Subirá D, Cullen M, Te Marvelde JG, van der Velden VH, Preijers FW, Chu SC, Feuillard J, Guérin E, Psarra K, Porwit A, Saft L, Ireland R, Milne T, Béné MC, Witte BI, Della Porta MG, Kern W, van de Loosdrecht AA; IMDSFlow Working Group.

Haematologica. 2017 Feb;102(2):308-319. doi: 10.3324/haematol.2016.147835. Epub 2016 Oct 6.

10.

Mutations in idiopathic cytopenia of undetermined significance assist diagnostics and correlate to dysplastic changes.

Hansen JW, Westman MK, Sjö LD, Saft L, Kristensen LS, Ørskov AD, Treppendahl M, Andersen MK, Grønbaek K.

Am J Hematol. 2016 Dec;91(12):1234-1238. doi: 10.1002/ajh.24554. Epub 2016 Nov 8.

11.

TERT rs2736100 genotypes are associated with differential risk of myeloproliferative neoplasms in Swedish and Chinese male patient populations.

Dahlström J, Liu T, Yuan X, Saft L, Ghaderi M, Wei YB, Lavebratt C, Li P, Zheng C, Björkholm M, Xu D.

Ann Hematol. 2016 Oct;95(11):1825-32. doi: 10.1007/s00277-016-2787-7. Epub 2016 Aug 25.

12.

Perturbations of the endocannabinoid system in mantle cell lymphoma: correlations to clinical and pathological features.

Wasik AM, Nygren L, Almestrand S, Zong F, Flygare J, Wennerholm SB, Saft L, Andersson P, Kimby E, Wahlin BE, Christensson B, Sander B.

Oncoscience. 2014 Sep 4;1(8):550-7. eCollection 2014.

13.

Detection of central nervous system involvement in childhood acute lymphoblastic leukemia by cytomorphology and flow cytometry of the cerebrospinal fluid.

Ranta S, Nilsson F, Harila-Saari A, Saft L, Tani E, Söderhäll S, Porwit A, Hultdin M, Noren-Nyström U, Heyman M.

Pediatr Blood Cancer. 2015 Jun;62(6):951-6. doi: 10.1002/pbc.25363. Epub 2014 Dec 24.

PMID:
25545289
14.

Dendritic cells in bone marrow at diagnosis and after chemotherapy in adult patients with acute myeloid leukaemia.

Derolf AR, Laane E, Björklund E, Saft L, Björkholm M, Porwit A.

Scand J Immunol. 2014 Dec;80(6):424-31. doi: 10.1111/sji.12223.

15.

A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.

Svensson T, Chowdhury O, Garelius H, Lorenz F, Saft L, Jacobsen SE, Hellström-Lindberg E, Cherif H.

Eur J Haematol. 2014 Nov;93(5):439-45. doi: 10.1111/ejh.12383. Epub 2014 Jun 14.

PMID:
24853277
16.

p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).

Saft L, Karimi M, Ghaderi M, Matolcsy A, Mufti GJ, Kulasekararaj A, Göhring G, Giagounidis A, Selleslag D, Muus P, Sanz G, Mittelman M, Bowen D, Porwit A, Fu T, Backstrom J, Fenaux P, MacBeth KJ, Hellström-Lindberg E.

Haematologica. 2014 Jun;99(6):1041-9. doi: 10.3324/haematol.2013.098103. Epub 2014 Mar 28.

17.

Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial.

Tobiasson M, Dybedahl I, Holm MS, Karimi M, Brandefors L, Garelius H, Grövdal M, Högh-Dufva I, Grønbæk K, Jansson M, Marcher C, Nilsson L, Kittang AO, Porwit A, Saft L, Möllgård L, Hellström-Lindberg E.

Blood Cancer J. 2014 Mar 7;4:e189. doi: 10.1038/bcj.2014.8.

18.

Bone marrow dendritic cells are reduced in patients with high-risk myelodysplastic syndromes.

Saft L, Björklund E, Berg E, Hellström-Lindberg E, Porwit A.

Leuk Res. 2013 Mar;37(3):266-73. doi: 10.1016/j.leukres.2012.10.010. Epub 2012 Nov 13.

PMID:
23153526
19.

Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study.

Della Porta MG, Picone C, Pascutto C, Malcovati L, Tamura H, Handa H, Czader M, Freeman S, Vyas P, Porwit A, Saft L, Westers TM, Alhan C, Cali C, van de Loosdrecht AA, Ogata K.

Haematologica. 2012 Aug;97(8):1209-17. doi: 10.3324/haematol.2011.048421. Epub 2012 Feb 7.

20.

Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.

Möllgård L, Saft L, Treppendahl MB, Dybedal I, Nørgaard JM, Astermark J, Ejerblad E, Garelius H, Dufva IH, Jansson M, Jädersten M, Kjeldsen L, Linder O, Nilsson L, Vestergaard H, Porwit A, Grønbæk K, Hellström-Lindberg E.

Haematologica. 2011 Jul;96(7):963-71. doi: 10.3324/haematol.2010.039669. Erratum in: Haematologica. 2011 Aug;96(8):1240. Lindberg, Eva Hellström [corrected to Hellström-Lindberg, Eva].

21.

TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.

Jädersten M, Saft L, Smith A, Kulasekararaj A, Pomplun S, Göhring G, Hedlund A, Hast R, Schlegelberger B, Porwit A, Hellström-Lindberg E, Mufti GJ.

J Clin Oncol. 2011 May 20;29(15):1971-9. doi: 10.1200/JCO.2010.31.8576. Epub 2011 Apr 25.

PMID:
21519010
22.

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.

Jädersten M, Saft L, Pellagatti A, Göhring G, Wainscoat JS, Boultwood J, Porwit A, Schlegelberger B, Hellström-Lindberg E.

Haematologica. 2009 Dec;94(12):1762-6. doi: 10.3324/haematol.2009.011528. Epub 2009 Oct 1.

23.

Reliability of the reported size of removed colorectal polyps.

Rubio CA, Grimelius L, Lindholm J, Hamberg H, Porwit A, Elmberger G, Höög A, Kanter L, Eriksson E, Stemme S, Orrego A, Saft L, Petersson F, De La Torre M, Ekström C, Astrom K, Rundgren A, Djokic M, Chandanos E, Lenander C, Machado M, Nilsson P, Mattsson L.

Anticancer Res. 2006 Nov-Dec;26(6C):4895-9.

24.

[Electronystagmography in complications of cranial trauma].

Saft L, Reynaud J.

Rev Otoneuroophtalmol. 1972 May-Jun;44(3):281-4. French. No abstract available.

PMID:
4661831
25.

[Nasal granuloma of unknown etiology].

Ardouin P, Saft L, Jobard P, Benatre A.

Rev Laryngol Otol Rhinol (Bord). 1967;88:Suppl:22-8. French. No abstract available.

PMID:
6062625
26.

[The sensori-motor auditory reaction time in normal and dyslexic children].

Ardouin P, Boulard P, Saft L, de Lauture H.

Rev Laryngol Otol Rhinol (Bord). 1966 Sep-Oct;87(9):693-703. French. No abstract available.

PMID:
5976746
27.

[Objective electro-encephalographic audiometry].

Saft L.

Rev Laryngol Otol Rhinol (Bord). 1966 Sep-Oct;87(9):633-89. Review. French. No abstract available.

PMID:
5341661
28.

[Barré-Liéou syndrome in otorhinolaryngologic practice].

Ardouin P, Gouaze A, Saft L.

Rev Otoneuroophtalmol. 1966 Jan-Feb;38(1):21-40. French. No abstract available.

PMID:
5931796
29.

[Cochlear anoxia due to arterial compression. Experimental study].

SAFT L.

Ann Otolaryngol Chir Cervicofac. 1963 Jul-Aug;80:728-31. French. No abstract available.

PMID:
13976036
30.

[Cochleo-toxic effects of antibiotics and the value of exploratory function tests].

SAFT L, BLOCH A.

Ann Otolaryngol Chir Cervicofac. 1963 Jul-Aug;80:724-8. French. No abstract available.

PMID:
13976035
31.

[Electro-physiological and histological study of the ototoxicity of certain antibiotics].

ARDOUIN P, SAFT L, JOBARD P.

Acta Otolaryngol. 1963 Mar-Apr;56:106-12. French. No abstract available.

PMID:
14041518
32.

[Experimental ischemia of the cochlea. Study by means of tests of electrical activity].

SAFT L.

C R Seances Soc Biol Fil. 1962;156:1145-8. French. No abstract available.

PMID:
13976037
33.

[Direct pre- & postoperative audiometry].

SAFT L.

Rev Esp Otoneurooftalmol Neurocir. 1957 Mar-Apr;16(90):119-29. Spanish. No abstract available.

PMID:
13453960

Supplemental Content

Support Center